Staging systems of lung cancer

A. M. Patel, W. F. Dunn, V. F. Trastek

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The staging of lung cancer involves assessment of the anatomic extent of disease based on the best available data. Such a definition of neoplastic burden facilitates the systematic analysis and meaningful communication of diagnostic, therapeutic, and prognostic information. Clinical staging involves the best estimate of extent of disease before performance of surgical resection or biopsy procedures (or both). Surgical-pathologic staging is based on the histopathologic analysis of resected specimens, including determining the extent of local and regional disease. During the past 50 years, two major classification schemes for staging of lung cancer have evolved-one for non-small-cell lung cancers (the TNM system, indicating the status of primary tumor [T], regional lymph node [N], and metastatic [M] involvement) and the other for small-cell carcinoma of the lung (based on limited versus extensive disease). In this report, we review the evolution of the current staging systems used for primary lung cancer and their prognostic implications.

Original languageEnglish (US)
Pages (from-to)475-482
Number of pages8
JournalMayo Clinic Proceedings
Volume68
Issue number5
StatePublished - 1993

Fingerprint

Lung Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Lymph Nodes
Biopsy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Patel, A. M., Dunn, W. F., & Trastek, V. F. (1993). Staging systems of lung cancer. Mayo Clinic Proceedings, 68(5), 475-482.

Staging systems of lung cancer. / Patel, A. M.; Dunn, W. F.; Trastek, V. F.

In: Mayo Clinic Proceedings, Vol. 68, No. 5, 1993, p. 475-482.

Research output: Contribution to journalArticle

Patel, AM, Dunn, WF & Trastek, VF 1993, 'Staging systems of lung cancer', Mayo Clinic Proceedings, vol. 68, no. 5, pp. 475-482.
Patel AM, Dunn WF, Trastek VF. Staging systems of lung cancer. Mayo Clinic Proceedings. 1993;68(5):475-482.
Patel, A. M. ; Dunn, W. F. ; Trastek, V. F. / Staging systems of lung cancer. In: Mayo Clinic Proceedings. 1993 ; Vol. 68, No. 5. pp. 475-482.
@article{879b99a7e5a94315accb26d251db8e01,
title = "Staging systems of lung cancer",
abstract = "The staging of lung cancer involves assessment of the anatomic extent of disease based on the best available data. Such a definition of neoplastic burden facilitates the systematic analysis and meaningful communication of diagnostic, therapeutic, and prognostic information. Clinical staging involves the best estimate of extent of disease before performance of surgical resection or biopsy procedures (or both). Surgical-pathologic staging is based on the histopathologic analysis of resected specimens, including determining the extent of local and regional disease. During the past 50 years, two major classification schemes for staging of lung cancer have evolved-one for non-small-cell lung cancers (the TNM system, indicating the status of primary tumor [T], regional lymph node [N], and metastatic [M] involvement) and the other for small-cell carcinoma of the lung (based on limited versus extensive disease). In this report, we review the evolution of the current staging systems used for primary lung cancer and their prognostic implications.",
author = "Patel, {A. M.} and Dunn, {W. F.} and Trastek, {V. F.}",
year = "1993",
language = "English (US)",
volume = "68",
pages = "475--482",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Staging systems of lung cancer

AU - Patel, A. M.

AU - Dunn, W. F.

AU - Trastek, V. F.

PY - 1993

Y1 - 1993

N2 - The staging of lung cancer involves assessment of the anatomic extent of disease based on the best available data. Such a definition of neoplastic burden facilitates the systematic analysis and meaningful communication of diagnostic, therapeutic, and prognostic information. Clinical staging involves the best estimate of extent of disease before performance of surgical resection or biopsy procedures (or both). Surgical-pathologic staging is based on the histopathologic analysis of resected specimens, including determining the extent of local and regional disease. During the past 50 years, two major classification schemes for staging of lung cancer have evolved-one for non-small-cell lung cancers (the TNM system, indicating the status of primary tumor [T], regional lymph node [N], and metastatic [M] involvement) and the other for small-cell carcinoma of the lung (based on limited versus extensive disease). In this report, we review the evolution of the current staging systems used for primary lung cancer and their prognostic implications.

AB - The staging of lung cancer involves assessment of the anatomic extent of disease based on the best available data. Such a definition of neoplastic burden facilitates the systematic analysis and meaningful communication of diagnostic, therapeutic, and prognostic information. Clinical staging involves the best estimate of extent of disease before performance of surgical resection or biopsy procedures (or both). Surgical-pathologic staging is based on the histopathologic analysis of resected specimens, including determining the extent of local and regional disease. During the past 50 years, two major classification schemes for staging of lung cancer have evolved-one for non-small-cell lung cancers (the TNM system, indicating the status of primary tumor [T], regional lymph node [N], and metastatic [M] involvement) and the other for small-cell carcinoma of the lung (based on limited versus extensive disease). In this report, we review the evolution of the current staging systems used for primary lung cancer and their prognostic implications.

UR - http://www.scopus.com/inward/record.url?scp=0027243259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027243259&partnerID=8YFLogxK

M3 - Article

C2 - 8386791

AN - SCOPUS:0027243259

VL - 68

SP - 475

EP - 482

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -